Clinical trials: COPD Exacerbations
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study
This trial is a randomized, double-blind, parallel-group, multicenter study to be conducted in the United States. The purpose of the study is to evaluate the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT01110200
- Testing
- ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID
- Where
- 103 sites in United States, Argentina and 1 more
- Volunteers
- 639 people
- Sponsor
- GlaxoSmithKline
COPD
Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or…
- Trial name
- CLOUD (NCT02346292)
- Where
- 30 sites in Russia
- Volunteers
- 1,250 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe…
- Trial name
- EROS+CP (US) (NCT06742736)
- Testing
- BGF
- Where
- United States
- Volunteers
- 13,000 people
- Sponsor
- AstraZeneca
Chronic Obstructive Lung Disease, Acute Exacerbation of COPD
Are Comorbidities Related to Frequent Severe Exacerbations of AECOPD
INTRODUCTION: Relationship between comorbidities and COPD is two-sided. While the number of comorbidities increasing, the frequency of acute exacerbations of COPD (AECOPD) is increasing, too.
- Conditions
- Chronic Obstructive Lung Disease, Acute Exacerbation of COPD, Comorbidities and Coexisting Conditions
- Trial name
- NCT05504993
- Testing
- Frequency of AECOPD
- Where
- Turkey (Türkiye)
- Volunteers
- 92 people
- Sponsor
- Ankara University
Chronic Obstructive Pulmonary Disease (COPD)
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol [BGF] in a real-world setting.
- Trial name
- CHRONICLES (NCT06511193)
- Testing
- Budenoside/Glycopyrronium/Formoterol
- Where
- Canada
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, COPD
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations.
- Trial name
- ROMEO (NCT07566195)
- Testing
- Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
- Where
- 13 sites in France
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive Patients Admitted in Emergency Department for Acute Exacerbation
Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER
The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).
- Trial name
- UTAPE BPCO (NCT01857947)
- Testing
- AECOPD Mr proADM
- Where
- 2 sites in France
- Volunteers
- 370 people
- Sponsor
- ThermoFisher Scientific Brahms Biomarkers France
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe…
- Trial name
- TITANIA (NCT05158387)
- Testing
- Tozorakimab
- Where
- 212 sites in United States, Australia and 18 more
- Volunteers
- 1,172 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with…
- Trial name
- ENDURA-2 (NCT06961214)
- Testing
- Depemokimab
- Where
- 193 sites in United States, Argentina and 14 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
Respiratory Synctial Virus, COPD
Respiratory Syncytial Virus Infection In Exacerbations of Chronic Obstructive Pulmonary Diasease: The RECODE Study
The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD)…
- Conditions
- Respiratory Synctial Virus, COPD, Chronic Obstructive Pulmonary Disease (COPD), Exacerbation of COPD
- Trial name
- RECODE (NCT06735612)
- Where
- Spain
- Volunteers
- 716 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
COPD Exacerbation, Periodontal Health
Efficacy of Periodontal Treatment on Systemic Inflammation and for Prevention of Exacerbations in Patients With COPD
Current data are showing a potential link between inflammatory biomarkers in chronic periodontitis and COPD. However the impact of periodontal treatment on systemic inflammation as measured by biomarkers and time to occurrence of…
- Trial name
- Expertention (NCT03279718)
- Testing
- Periodontal Treatment
- Where
- 3 sites in Germany
- Volunteers
- 4 people
- Sponsor
- Heidelberg University
Chronic Obstructive Pulmonary Disease
Infectious Etiology of Acute Exacerbations of COPD
To assess the infectious etiology related to acute exacerbation of COPD in Hong Kong
- Trial name
- NCT00441389
- Volunteers
- 500 people
- Sponsor
- Chinese University of Hong Kong
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset
COPD Readmissions Prediction- ReCOPD Project
To develop predictive models for short-term readmission (60 days) and medium term (one year) for patients with an exacerbation of COPD (eCOPD) which are admitted to any of the participant hospitals.
- Trial name
- ReCOPD (NCT03227211)
- Where
- 8 sites in Spain
- Volunteers
- 1,500 people
- Sponsor
- Hospital Galdakao-Usansolo
Anxiety, COPD
Escitalopram in Anxiety Associated Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Anxiety and depression are common in patients with severe chronic obstructive pulmonary disease (COPD). Frequently exacerbation's of breathlessness are associated with panic/fear and indeed this may be the main cause for the for…
- Trial name
- NCT01522092
- Testing
- escitalopram
- Where
- United Kingdom
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Chronic Obstructive Pulmonary Disease
Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
This is a parallel group, double-blind, placebo controlled, multi-centre, randomised trial. 60 patients to be included who are adult patients admitted to hospital with a clinical diagnosis of acute exacerbation of Chronic…
- Trial name
- NCT01176318
- Testing
- Erdosteine
- Where
- United Kingdom
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Obstructive Chronic Bronchitis With Acute Exacerbation
Respiratory Therapy in COPD Exacerbations
The purpose of this study is to determine effectiveness, feasibility and safety/tolerance of Respiratory Therapy in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease.
- Trial name
- TRESEPOCAS (NCT02125747)
- Testing
- No Respiratory Therapy, Respiratory Therapy
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Parc de Salut Mar
COPD, COPD Exacerbation
A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination
Inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) combination is commonly prescribed to treat COPD; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (LAMA) to…
- Trial name
- RETRIEVE (NCT03858348)
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
COPD
Management of COPD Patients With BoraCare® Remote Monitoring Solution Including BVS3 Early Detection Score for COPD Exacerbations
The goal of this clinical trial is to demonstrate the superiority of remote monitoring with the Bora Care solution in patients with COPD and frequent exacerbations (experimental group) compared to conventional follow-up alone…
- Trial name
- AUSTRAAL (NCT06523140)
- Testing
- Boracare remote monitoring solution
- Where
- 10 sites in France
- Volunteers
- 380 people
- Sponsor
- Biosency
Pulmonary Disease, Chronic Obstructive
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative…
- Trial name
- NCT00527826
- Testing
- Salmeterol / Fluticasone (50/500 µg) BID fixed combination, Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
- Where
- 23 sites in Germany
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy
COPD is one of the most important causes of morbidity and mortality and supposes a sanitary problem in Europe and USA. Patients with COPD usually have 1-2 episodes of acute exacerbation of COPD (AECOPD) per year, being these the…
- Trial name
- AEPOC-ATB (NCT01091493)
- Testing
- Moxifloxacin
- Where
- 4 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica